Product Information
OLMESARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TAB is a generic product labeled by NorthStar Rx LLC, priced at $0.2196 per EA under NDC 72603029102. Its NADAC has been published 53 times since Oct 1, 2025.
FDA first approved this application on Jun 1, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
OLMESARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TAB
OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDEStrength
12.5; 40 mg/1; mg/1
Manufacturer
NorthStar Rx LLCNDC
72603029102
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMILApproval Type
Generic (ANDA)
FDA Application
ANDA204801FDA Approved
6/1/2023
TE Code
AB
On Market Since
4/8/2024
Pharmacological Classes
Price Statistics
The NADAC for OLMESARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TAB has been published 53 times since Oct 1, 2025, and over the history we have for it it has declined 4.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2196 per EA |
|---|---|
| All-time high | $0.2393 (Sep 16, 2026) |
| All-time low | $0.2149 (Feb 18, 2026) |
| 52-week high | $0.2393 |
| 52-week low | $0.2149 |
| Median price | $0.2290 |
| Average price | $0.2286 |
| Largest weekly change | -8.2% (Sep 23, 2026) |
| Weeks tracked | 53 |
| Tracking since | Oct 1, 2025 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
NorthStar Rx LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OLMESARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for OLMESARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TAB, manufactured by NorthStar Rx LLC, is $0.2196 per EA (NDC 72603029102), effective Sep 30, 2026.
How has the price of OLMESARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TAB changed over time?
Over the history we have for it, the NADAC for OLMESARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TAB has declined 4.1%. It has been tracked across 53 weekly CMS publications since Oct 1, 2025.
What are the highest and lowest recorded NADAC prices for OLMESARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TAB?
Since Oct 1, 2025, the NADAC for OLMESARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TAB has ranged from a low of $0.2149 (Feb 18, 2026) to a high of $0.2393 (Sep 16, 2026), with a median of $0.2290 per EA.
Are there cheaper alternatives to OLMESARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TAB?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as OLMESARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures OLMESARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TAB?
OLMESARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TAB (NDC 72603029102) is labeled by NorthStar Rx LLC, and CMS classifies it as a generic product.